Clinical information on imaging referrals for suspected or known axial spondyloarthritis: recommendations from the Assessment of Spondyloarthritis International Society (ASAS).
Autor: | Diekhoff T; Department of Radiology, Freie Universität Berlin, Berlin, Germany torsten.diekhoff@charite.de., Giraudo C; Department of Medicine, University of Padova, Padova, Italy., Machado PM; Department of Neuromuscular Diseases, University College London, London, UK.; University College London Hospitals NHS Foundation Trust, London, UK., Mallinson M; Ankylosing Spondylitis International Federation (ASIF), London, UK., Eshed I; Radiology, Sheba Medical Center, Tel Hashomer, Israel., Haibel H; Med. Dep I, Rheumatology, Charité University, Berlin, Germany., Hermann KG; Department of Radiology, Freie Universität Berlin, Berlin, Germany., de Hooge M; VIB Center of Inflammation Research, Ghent University, Gent, Belgium., Jans L; Radiology, Ghent University Hospital, Ghent, Belgium., Jurik AG; Department of Radiology, Aarhus University Hospital, Aarhus, Denmark., Lambert RG; Radiology and Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada., Maksymowych W; Medicine, University of Alberta, Edmonton, Alberta, Canada., Marzo-Ortega H; Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK., Navarro-Compán V; Rheumatology, Leiden University Medical Center, Leiden, The Netherlands., Østergaard M; Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Glostrup, Denmark., Pedersen SJ; Department of Rheumatology, Copenhagen University Hospital Glostrup, Glostrup, Denmark.; Copenhagen Center for Arthritis Research, Glostrup, Denmark., Reijnierse M; Radiology, Leiden University Medical Center, Leiden, The Netherlands., Rudwaleit M; Internal Medicine and Rheumatology, Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany., Sommerfleck FA; Rheumatology, Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina., Weber U; Rheumatology, Practice Zenit, Schaffhausen, Switzerland., Baraliakos X; Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany., Poddubnyy D; Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Charité Universitätsmedizin Berlin, Berlin, Germany. |
---|---|
Jazyk: | angličtina |
Zdroj: | Annals of the rheumatic diseases [Ann Rheum Dis] 2024 Nov 14; Vol. 83 (12), pp. 1636-1643. Date of Electronic Publication: 2024 Nov 14. |
DOI: | 10.1136/ard-2024-226280 |
Abstrakt: | Objectives: This study aims to establish expert consensus recommendations for clinical information on imaging requests in suspected/known axial spondyloarthritis (axSpA), focusing on enhancing diagnostic clarity and patient care through guidelines. Materials and Methods: A specialised task force was formed, comprising 7 radiologists, 11 rheumatologists from the Assessment of Spondyloarthritis International Society (ASAS) and a patient representative. Using the Delphi method, two rounds of surveys were conducted among ASAS members. These surveys aimed to identify critical elements for imaging referrals and to refine these elements for practical application. The task force deliberated on the survey outcomes and proposed a set of recommendations, which were then presented to the ASAS community for a decisive vote. Results: The collaborative effort resulted in a set of six detailed recommendations for clinicians involved in requesting imaging for patients with suspected or known axSpA. These recommendations cover crucial areas, including clinical features indicative of axSpA, clinical features, mechanical factors, past imaging data, potential contraindications for specific imaging modalities or contrast media and detailed reasons for the examination, including differential diagnoses. Garnering support from 73% of voting ASAS members, these recommendations represent a consensus on optimising imaging request protocols in axSpA. Conclusion: The ASAS recommendations offer comprehensive guidance for rheumatologists in requesting imaging for axSpA, aiming to standardise requesting practices. By improving the precision and relevance of imaging requests, these guidelines should enhance the clinical impact of radiology reports, facilitate accurate diagnosis and consequently improve the management of patients with axSpA. Competing Interests: Competing interests: TD: speakers bureau: Canon MS, Lilly, MSD, Novartis, Pfizer and UCB; consultant: Lilly; grant/research support: Canon MS. CG: speakers bureau: Boehringer Ingelheim. VN-C: has received speakers fees from AbbVie, Eli Lilly, Fresenius Kabi, Janssen, MSD, Novartis, Pfizer, UCB Pharma; consultant of AbbVie, Eli Lilly, MSD, Novartis, Pfizer, UCB Pharma; grant/research support from AbbVie and Novartis. IE: speakers bureau: AbbVie, Novartis. HH: speakers bureau: AbbVie, MSD, Janssen, Roche, Sobi and Pfizer, consultant of Roche, Boehringer Ingelheim, Janssen, MSD, AbbVie, Novartis and Sobi. PMM: honoraria from AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, all unrelated to this manuscript, and is supported by the National Institute for Health Research (NIHR), University College London Hospitals (UCLH), Biomedical Research Centre (BRC). WM: speaking: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, UCB consultant: AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Novartis, Pfizer, UCB grants: AbbVie, Eli Lilly, Novartis, Pfizer, UCB. HM-O: research grants from Janssen, Novartis, Pfizer and UCB, honoraria/speaker fees from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Moonlake, Novartis, Pfizer, Takeda and UCB. MØ: speaker fees: AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MEDAC, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi and UCB. XB: consultant: AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, Gilead, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB; grant/research support: AbbVie, Amgen, BMS, Celgene, Eli Lilly, Merck, Novartis and UCB. MRu: speaker fees from and/or advisor for AbbVie, Boehringer Ingelheim, Eli Lilly, Janssen, Novartis, UCB. KGH: speaker fees from Novartis, MSD and Pfizer. Consulting for AbbVie and Calyx. Co-founder of BerlinFlame. SJP: speaking fees from MSD, Pfizer, AbbVie, UCB, Novartis; consulting fees and/or honoraria from AbbVie, UCB, Novartis and research support from AbbVie, MSD and Novartis. MRe: ISS grant; ASAS consultant. RGWL: consultant: Calyx, CARE Arthritis, Image Analysis Group. UW: speaker fees: Novartis, Eli Lilly. AGJ: none for this article. MdH: speaker fees from UBC. FAS: speaker fees: Novartis, Pfizer, AbbVie, Janssen. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ on behalf of EULAR.) |
Databáze: | MEDLINE |
Externí odkaz: |